MiniMed prices 28 million-share IPO at $20, will list on Nasdaq

MiniMed Group, Inc., the diabetes-focused unit carved out of Medtronic plc, priced its initial public offering at $20.00 per share for 28,000,000 shares, the company announced in a March 5 press release datelined GALWAY, Ireland and NORTHRIDGE, Calif. The shares are expected to begin trading on the Nasdaq Global Select Market on March 6, 2026, under the symbol "MMED," and the offering is expected to close on March 9, 2026, subject to customary closing conditions, the release said.

"MiniMed Group, Inc. (MiniMed), a subsidiary of Medtronic plc (Medtronic) (NYSE: MDT), today announced the pricing of its initial public offering (IPO) of 28,000,000 shares of its common stock at a price to the public of $20.00 per share," the press release states. The company also granted underwriters a 30-day option to purchase up to 4,200,000 additional shares at the initial public price less underwriting discounts and commissions.

Simple arithmetic from those figures yields gross proceeds of $560 million (28,000,000 x $20.00), based on the numbers in the filing notice. Medtronic will remain the controlling shareholder after the issuance, holding approximately 90.03% of MiniMed if the greenshoe is not exercised and about 88.70% if the underwriters buy the full 4.2 million extra shares, the release said. MiniMed said it intends to use a portion of net proceeds for general corporate purposes and the remainder, if any, to repay intercompany debt owed to Medtronic and as additional consideration for assets transferred in the separation.

The final $20 price comes after roadshow materials and an S-1 amendment reported on February 24 had indicated an expected price range of $25 to $28 per share. That earlier reporting, cited by Drugdeliverybusiness, Ainvest, Barchart and Kavout, projected potential gross proceeds up to $784 million at the $28 high end and saw the offering topping $900 million if the over-allotment were fully exercised. Those earlier estimates also included a midpoint net-proceeds figure of roughly $712.3 million and a stated aim to retain about $350 million in cash on hand for separation, according to Drugdeliverybusiness.

Analysts and trade press positioned the IPO as a strategic step in Medtronic's broader portfolio simplification, enabling the parent to concentrate on higher-margin cardiovascular and neuroscience businesses while unlocking standalone value in diabetes care. MiniMed reported roughly $2.8 billion in revenue in fiscal 2025, and trade reporting cited by Barchart said the unit accounted for about 8 percent of Medtronic's revenue that year. Product drivers named in analyst coverage include the 780G insulin pump and enhanced glucose monitoring systems, while risks noted include regulatory scrutiny and cybersecurity concerns.

Market reaction heading into the listing was cautious. Kavout cited contemporaneous Medtronic metrics including a trading price of $97.52 and a market capitalization of $125.08 billion, reflecting investor attention to both the value being carved out and the parent company's ongoing earnings profile. The MiniMed press release included standard cautionary language about future uncertainties: "The ability of MiniMed or Medtronic to achieve the anticipated benefits of the IPO may be materially affected by such factors as changes to the business, results of operations or financial condition of MiniMed or Medtronic, changes in the medical products industry, adverse market or macroeconomic conditions and other factors outside the control of MiniMed or Medtronic."

Investors will watch subscription details, any exercise of the greenshoe and the first-day trading performance to gauge market appetite for a standalone diabetes device company that will begin public life with Medtronic as its dominant owner.